The siRNA knockdown of IFN Regulatory Factor 5 (IRF5) in the human plasmacytoid dendritic cell line Gen2.2 prevented IFNβ production induced by compound CL097, a ligand for Toll-like receptor 7 (TLR7). CL097 also stimulated the phosphorylation of IRF5 at Ser462 and stimulated the nuclear translocation of wild-type IRF5, but not the IRF5[Ser462Ala] mutant. The CL097-stimulated phosphorylation of IRF5 at Ser462 and its nuclear translocation was prevented by the pharmacological inhibition of protein kinase IKKβ or the siRNA knockdown of IKKβ or its "upstream" activator, the protein kinase TAK1. Similar results were obtained in a murine macrophage cell line stimulated with the TLR7 agonist compound R848 or the nucleotide oligomerization domain 1 (NOD1) agonist KF-1B. IKKβ phosphorylated IRF5 at Ser462 in vitro and induced the dimerization of wild-type IRF5 but not the IRF5[S462A] mutant. These findings demonstrate that IKKβ activates two "master" transcription factors of the innate immune system, IRF5 and NF-κB.T he transcription factor IFN Regulatory Factor 5 (IRF5) has a critical role in the production of proinflammatory cytokines. The secretion of interleukin 12 (IL-12), IL-6, and TNFα by ligands that activate Toll-like receptor 3 (TLR3), TLR4, TLR5, and TLR9, is greatly impaired in macrophages, conventional dendritic cells (cDCs), and plasmacytoid dendritic cells (pDCs) of mice that do not express IRF5 (1). However, the role of IRF5 in type 1 IFN production in pDCs has been less clear. The TLR9-stimulated secretion of IFNα was initially reported to be similar in pDCs from IRF5-deficient and wild-type mice (1), but a later study found that the TLR7-or TLR9-stimulated production of IFNα was reduced in pDCs from IRF5-deficient mice (2). Subsequently, some IRF5-deficient mouse lines were shown to carry a second mutation in the gene encoding the guanine nucleotide exchange factor (dedicator of cytokinesis 2 (Dock2), and it was reported that TLR9-stimulated IFNα secretion was largely intact in pDCs from mice where this secondary mutation had been eliminated (3). A further study using pDCs from IRF5-deficient mice, carrying or not carrying the DOCK2 mutation, confirmed that IRF5 had little effect on TLR9-stimulated IFNα secretion, but indicated an important role for IRF5 in the secretion of IFNβ (4). IRF5 was also required for the TLR9-stimulated production of IFNβ in the human pDC line CAL-1 (5) and for the production of IFNβ induced by streptococcal RNA in cDCs (6) and by the fungal pathogen Candida albicans in a pathway dependent on the Dectin 1 and Dectin 2 receptors (7). IRF5 was also found to be needed for the production of IFNβ by a small subset of viruses (8, 9). Thus, IRF5 does appear to be a key regulator of IFNβ production by several pathogens.IRF5 is present in a latent form in the cell cytosol but accumulates in the nucleus to stimulate gene transcription following viral infection (10, 11) or stimulation with the TLR7/TLR8 agonist R848 (9). The nuclear export signal (NES) (12) of IRF5 therefore appears to ...